Healthcare / BiotechnologyNasdaqCM
$3.08
+0.18 (+6.21%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-21.8M · quality 85.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
35/100
D
Piotroski
0/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$195M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-78.3%
↓Gross Margin
N/A
•Debt/Equity
0.03
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
1.02x
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-22.4M · FCF $-22.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | — | — | $41.1M | $36.1M | $15.8M |
| Net Income | $-22.4M | $-22.4M | $-8.1M | $-13.3M | $-62.4M |
| EBITDA | $-23.5M | $-23.5M | $-8.1M | $-12.1M | $-61.3M |
| EPS | -0.39 | -0.39 | -0.23 | -0.38 | -1.85 |
| Operating Margin | — | — | -20.1% | -40.2% | -247.6% |
| Net Margin | — | — | -19.6% | -37.0% | -396.1% |
| Balance Sheet | |||||
| Debt/Equity | 0.03 | 0.03 | 0.02 | 0.04 | 0.32 |
| Current Ratio | 18.62 | 18.62 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-22.8M | $-22.8M | $-19.1M | $-21.8M | $-9.0M |
| Returns | |||||
| ROE | -78.3% | -78.3% | -42.3% | -59.1% | -195.4% |
| Valuation | |||||
| P/B | 6.17 | 6.17 | 1.45 | 1.26 | 1.21 |
| Growth & Yield | |||||
| Revenue Growth | — | — | 13.9% | 129.0% | — |
| EPS Growth | -69.6% | -69.6% | 39.5% | 79.5% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+689.7%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.23 → -0.39
Residual
+689.7%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.